Bio­nom­ics’ stock sky­rock­ets 340% af­ter PTSD can­di­date pass­es PhI­Ib test

Bio­nom­ics tout­ed the reg­is­tra­tional po­ten­tial of its post-trau­mat­ic stress dis­or­der drug af­ter it hit the pri­ma­ry end­point in a Phase IIb tri­al, trig­ger­ing the com­pa­ny’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER